Clinical Trial Update: Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) [Phase 3]

View source ↗

Summary

Phase 3 STRIDE-9 trial data show safety and immunogenicity of V116 in vaccine-naïve Japanese older adults for pneumococcal disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• V116

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-05-30